HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Joseph F. Sabik Markus K. Heinemann Frank L. Hanley Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sabik, J. F. Articles by Castaneda, S. b. A. R. Search for Related Content PubMed PubMed Citation Articles by Sabik, J. F. Articles by Castaneda, S. b. A. R.

J Thorac Cardiovasc Surg 1994;107:116-125
© 1994 Mosby, Inc.

SURGERY FOR CONGENITAL HEART DISEASE

High-dose steroids prevent placental dysfunction after fetal cardiac bypass

Boston, Mass.

Sponsored by Aldo R. Castaneda, MD

Boston, Mass.

From the Department of Cardiovascular Surgery, Children's Hospital of Boston, Harvard Medical School, Boston, Mass.

Address for reprints: Frank L. Hanley, MD, Department of Cardiothoracic Surgery, University of California at San Francisco, 505 Parnassus Ave., San Francisco, CA 94143.

Abstract

Surgical treatment of certain congenital heart lesions in utero may have a therapeutic advantage over postnatal repair or palliation. For fetal heart surgery to be possible, a method to support the fetal circulation is necessary. Early experimental attempts at fetal cardiac bypass were unsuccessful because of increased placental vascular resistance during and after fetal cardiac bypass, which led to decreased placental flow, fetal asphyxia, and death. Our laboratory has demonstrated that the administration of indomethacin (a cyclooxygenase inhibitor) during fetal cardiac bypass prevents this increase in placental vascular resistance during and after fetal cardiac bypass. The specific mechanism by which indomethacin achieves this effect is likely to be either by inhibiting the production of a placental vasoconstrictive prostaglandin or by diverting substrate from the cyclooxygenase pathway to the lipoxygenase pathway, thereby potentially increasing the production of a placental vasodilating leukotriene. To examine these potential mechanisms in more detail, we inhibited both prostaglandin and leukotriene synthesis at the phospholipase stage with high-dose steroids. Fourteen fetal lambs were used in the study. Six animals received indomethacin (3 mg/kg), four received high-dose steroids (Solu-Medrol 50 mg/kg), and four animals were used as controls. Observations were made during a 1-hour prebypass period, a 30-minute bypass period, and a 2-hour postbypass period. Placental blood flow and placental vascular resistance were calculated at four times during the experiments: before sternotomy; after sternotomy; during bypass at 30 minutes; and 30 minutes after cessation of bypass. Similar to indomethacin, high-dose steroid administration during fetal cardiac bypass prevents the rise in placental vascular resistance and preserves placental blood flow during and after fetal cardiac bypass. This study suggests that the production of a placental vasoconstrictive prostaglandin is responsible for the increase in placental vascular resistance and decrease in placental blood flow observed after fetal cardiac bypass. (J THORAC CARDIOVASC SURG 1994;107:116-25)

This article has been cited by other articles:

				C. T. Lam, S. Sharma, R. S. Baker, J. Hilshorst, J. Lombardi, K. E. Clark, and P. Eghtesady Fetal stress response to fetal cardiac surgery. Ann. Thorac. Surg., May 1, 2008; 85(5): 1719 - 1727. [Abstract] [Full Text] [PDF]

				M. Jahangiri and J. Clark Surgery for type A aortic dissection in pregnant patients with Marfan syndrome Eur. J. Cardiothorac. Surg., February 1, 2006; 29(2): 264 - 264. [Full Text] [PDF]

				P. Eghtesady, J. A. Sedgwick, J. L. Schenbeck, C. Lam, J. Lombardi, R. Ferguson, A. Gardner, J. McNamara, and P. Manning Maternal-Fetal Interactions in Fetal Cardiac Surgery Ann. Thorac. Surg., January 1, 2006; 81(1): 249 - 256. [Abstract] [Full Text] [PDF]

				A. Ikai, R. K. Riemer, C. Ramamoorthy, S. Malhatra, L. Cassorla, G. Amir, F. L. Hanley, and V. M. Reddy Preliminary results of fetal cardiac bypass in nonhuman primates J. Thorac. Cardiovasc. Surg., January 1, 2005; 129(1): 175 - 181. [Abstract] [Full Text] [PDF]

				Y. Oishi, M. Masuda, T. Yasutsune, N. Boku, S. Tokunaga, S. Morita, and H. Yasui Impaired Endothelial Function of the Umbilical Artery After Fetal Cardiac Bypass Ann. Thorac. Surg., December 1, 2004; 78(6): 1999 - 2003. [Abstract] [Full Text] [PDF]

				A. Carotti, F. Emma, S. Picca, E. Iannace, S. B. Albanese, M. Grigioni, F. Meo, M. Sciarra, and R. M. Di Donato Inflammatory response to cardiac bypass in ewe fetuses: effects of steroid administration or continuous hemodiafiltration J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 1839 - 1848. [Abstract] [Full Text] [PDF]

				M. Jahangiri, J. Clark, F. Prefumo, C. Pumphrey, and D. Ward Cardiac surgery during pregnancy: pulsatile or nonpulsatile perfusion? J. Thorac. Cardiovasc. Surg., September 1, 2003; 126(3): 894 - 895. [Full Text] [PDF]

				R. S. Assad, F. Y. Lee, and F. L. Hanley Placental compliance during fetal extracorporeal circulation J Appl Physiol, May 1, 2001; 90(5): 1882 - 1886. [Abstract] [Full Text] [PDF]

				C. Vedrinne, F. Tronc, S. Martinot, J. Robin, A.-M. Allevard, M. Vincent, J. J. Lehot, M. Franck, and G. Champsaur Better preservation of endothelial function and decreased activation of the fetal renin-angiotensin pathway with the use of pulsatile flow during experimental fetal bypass J. Thorac. Cardiovasc. Surg., October 1, 2000; 120(4): 770 - 777. [Abstract] [Full Text] [PDF]

				A. J. Parry, E. Petrossian, D. B. McElhinney, V. M. Reddy, and F. L. Hanley Neutrophil degranulation and complement activation during fetal cardiac bypass Ann. Thorac. Surg., August 1, 2000; 70(2): 582 - 589. [Abstract] [Full Text] [PDF]

				H. F. Tripp, R. M. Stiegel, and J. P. Coyle The use of pulsatile perfusion during aortic valve replacement in pregnancy Ann. Thorac. Surg., April 1, 1999; 67(4): 1169 - 1171. [Abstract] [Full Text] [PDF]

				V. M. Reddy, D. B. McElhinney, H. A. Rajasinghe, J. R. Liddicoat, K. Hendricks-Munoz, J. R. Fineman, and F. L. Hanley ROLE OF THE ENDOTHELIUM IN PLACENTAL DYSFUNCTION AFTER FETAL CARDIAC BYPASS J. Thorac. Cardiovasc. Surg., February 1, 1999; 117(2): 343 - 351. [Abstract] [Full Text] [PDF]

				G. Champsaur, C. Vedrinne, S. Martinot, F. Tronc, J. Robin, J. Ninet, and M. Franck FLOW-INDUCED RELEASE OF ENDOTHELIUM-DERIVED RELAXING FACTOR DURING PULSATILE BYPASS: EXPERIMENTAL STUDY IN THE FETAL LAMB J. Thorac. Cardiovasc. Surg., November 1, 1997; 114(5): 738 - 745. [Abstract] [Full Text]

				V. M. Reddy, J. R. Liddicoat, J. R. Klein, D. B. McElhinney, R. K. Wampler, and F. L. Hanley Fetal Cardiac Bypass Using an In-Line Axial Flow Pump to Minimize Extracorporeal Surface and Avoid Priming Volume Ann. Thorac. Surg., August 1, 1996; 62(2): 393 - 400. [Abstract] [Full Text]

				A. J. Parry and S. Westaby Cardiopulmonary Bypass During Pregnancy Ann. Thorac. Surg., June 1, 1996; 61(6): 1865 - 1869. [Abstract] [Full Text]

				V. M. Reddy, J. R. Liddicoat, J. R. Klein, R. K. Wampler, and F. L. Hanley LONG-TERM FETAL OUTCOME AFTER FETAL CARDIAC BYPASS: FETAL SURVIVAL TO FULL TERM AND ORGAN ABNORMALITIES J. Thorac. Cardiovasc. Surg., March 1, 1996; 111(3): 536 - 544. [Abstract] [Full Text]